The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
1987
year mood +0.38 · +0.00 to +0.64 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.75 -0.38 0 +0.38 +0.75 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov +0.64 Dec
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
+0.40+0.40+0.57+0.40+0.40+0.40+0.40+0.40+0.30+0.00+0.64+0.20

Healthcare sentiment is positive this month, driven primarily by the FDA’s approval of Genentech’s genetically engineered TPA, a significant advancement in clot-dissolving therapeutics that signals continued innovation momentum in biotech. While broader market conditions are stable, the sector’s gains are rooted in this regulatory greenlight, which reinforces confidence in R&D pipelines and near-term commercial potential for engineered biologics.

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 06, 2026
Top healthcare stories of 1987
Mar
FDA approves first AIDS treatment drug AZT, marketed by Burroughs Wellcome upi.com →

The FDA approved AZT (Retrovir), the first effective treatment for AIDS, developed by Burroughs Wellcome, for patients with advanced AIDS or related complex. Limited supply will prioritize severely immunocompromised patients, with initial distribution based on clinical need and availability. The approval signals a pivotal medical advancement, potentially driving demand and financial strain due to high annual costs of $7,000–$10,000 per patient.

Nov
FDA approves Genentech's genetically engineered clot-dissolving drug TPA upi.com →

The FDA approved Genentech's genetically engineered drug tPA for dissolving heart attack-causing clots, marking a major milestone for biotechnology. The drug, expected to generate up to $1 billion annually, improves heart function when administered quickly but carries bleeding risks. Approval boosts Genentech's market position and could drive significant revenue growth.